Search

For men undergoing surgery for localized prostate cancer, which is often diagnosed at an early, curable stage, functional outcomes are as important as oncological outcomes. Patient and tumor characteristics are [...]

Adding an extra dose of external-beam radiation therapy (EBRT) to the standard EBRT improved biochemical disease-free survival (bDFS) in patients with localized prostate cancer, according to findings from the phase [...]

Orlando, FL -- As ablative technologies have matured to the stage where they can be used for precise tissue destruction, there has been increasing interest in subtotal focal therapy for [...]

New data on outcomes of surgery, radiotherapy, and watchful waiting, along with studies of minimally invasive surgical approaches provided the core for the AUA meeting take-home messages on management of [...]

Active surveillance is becoming a very reasonable and appropriate "treatment" strategy for men with low-risk localized prostate cancer, as Large and Eggener eloquently describe in this review article. It is [...]

So here we go again with one more round in the battle of treatment options for localized prostate cancer. While more than 3 decades of such sparring has gotten us [...]

Management options for localized prostate cancer include radical prostatectomy (RP), radiation therapy (external-beam radiation therapy [EBRT] or brachytherapy), with and without androgen-deprivation therapy (ADT), or active surveillance, also known as watchful waiting. Ultimately, the choice of treatment is determined by a variety of factors, including institutional preference, individual physician judgment, patient preference, and resource availability. In this editorial, we make the case for radiation therapy (EBRT or brachytherapy) as the management modality of choice for localized prostate cancer., In 2008, approximately 186,000 American men were diagnosed with prostate cancer, resulting in about 28,600 deaths.[1] It is the most commonly diagnosed cancer, and second only to lung cancer as [...]

The optimal treatment for clinically localized prostate cancer is an ongoing subject of controversy.[1] As pointed out by Drs. Mirhadi and Sandler, no randomized trial has compared radical prostatectomy (RP) [...]

Socioeconomic factors predominantly explain racial and ethnic disparities in prostate cancer outcomes, according to a new study. Published in the March 15, 2006 issue of Cancer, the study found that [...]

San Antonio -- Urologists who might have bypassed the option of surgery to send patients with clinical T3 (cT3) disease directly to a radiation oncologist might want to rethink the [...]

When compared with the general population, mortality rates for men with prostate cancer are no higher, according to a study in the Journal of Clinical Oncology (2005; 23:441-7). Researchers at [...]

Orlando, FL -- A novel immunotherapy drug may increase the survival of hormonally refractive patients with asymptomatic, metastatic prostate cancer, according to the results of a small study with great [...]

Sacramento, CA -- Patients who undergo external beam radiation therapy (EBRT) either as primary treatment for prostate cancer or for post-prostatectomy positive margins are at increased risk of mortality if [...]

It is now widely accepted that accurate measurement of functional outcomes following prostate cancer treatment is best accomplished by using validated patient questionnaires to query patient health-related quality of life [...]

The advent of the PSA test and its adoption into mainstream practice has had a profound impact on the diagnosis and management of prostate cancer. Along with the advantages offered [...]

Atlanta -- Neoadjuvant docetaxel added to androgen suppression therapy and radiation therapy appears to be safe and active in patients with high-risk localized prostate cancer, according to findings of a [...]

Atlanta -- PSA doubling time (PSADT) appears to have limitations as a predictor of treatment outcome, according to results of a phase II, placebo-controlled trial of atrasentan (Xinlay) in patients [...]

* Statins appear to improve the outcomes of prostate cancer treatment with brachytherapy, according to a study in Urology (2005; 66:1150-4). Gregory S. Merrick, MD, of the Schiffler Cancer Center [...]

In patients with prostate cancer, measures of PSA kinetics are proving to be accurate predictors of outcomes as well as treatment efficacy in those patients who are receiving systemic therapy. [...]